Unichem Laboratories Ltd. — Regulatory Filings 2021

Jan 13, 2021

==> picture [190 x 43] intentionally omitted <==

January 13, 2021

Department of Corporate Services Mr. Hari K. Bombay Stock Exchange, Asst. Vice President - Operations Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001. Bandra (East), Mumbai – 400 051.

Ref: BSE Scrip Code – 506690: NSE Symbol – UNICHEMLAB

Dear Sir,

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg.

Thanking you,

For UNICHEM LABORATORIES LIMITED,

PRADEEP Digitally signed by PRADEEP BHANDARI BHANDARI Date: 2021.01.13 12:27:53 +05'30' PRADEEP BHANDARI Head- Legal & Company Secretary

==> picture [48 x 47] intentionally omitted <==

==> picture [189 x 32] intentionally omitted <==

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.

==> picture [190 x 43] intentionally omitted <==

Mumbai, Wednesday, January 13, 2021

PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval for its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (USFDA) to market a generic version of CELEBREX[®] (Celecoxib) Capsules of G.D. Searle LLC, Division of Pfizer Inc.

Celecoxib capsules are indicated for treatment of Osteoarthritis, Rheumatoid Arthritis Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Pain and Primary Dysmenorrhea. The product will be commercialized from Unichem’s Goa Plant.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at www.unichemlabs.com

For more information please contact:

Mr. Pradeep Bhandari Ph: +91-22-66888 404

E-mail: pradeep.bhandari@unichemlabs.com

Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

PRADEEP Digitally signed by PRADEEP BHANDARI BHANDARI Date: 2021.01.13 12:31:17 +05'30'

==> picture [49 x 47] intentionally omitted <==

==> picture [189 x 32] intentionally omitted <==

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.